
PROF
Profound Medical Corp.
$4.47
-$0.06(-1.32%)
18
Overall
--
Value
18
Tech
--
Quality
Market Cap
$135.39M
Volume
37.27K
52W Range
$3.90 - $9.17
Target Price
$12.31
Order:
Income Statement
Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|---|
REVENUE | |||||||
Total Revenue | $7.3M | $6.9M | $6.7M | $7.2M | $10.7M | ||
Total Revenue | $7.3M | $6.9M | $6.7M | $7.2M | $10.7M | ||
COST OF GOODS SOLD | |||||||
Cost of Revenue | $3.8M | $3.9M | $3.7M | $2.9M | $3.6M | ||
GROSS PROFIT | |||||||
Gross Profit | $3.5M | $3.0M | $3.0M | $4.3M | $7.0M | ||
OPERATING EXPENSES | |||||||
Operating Expenses | $22.3M | $33.2M | $29.5M | $33.0M | $40.1M | ||
Research & Development | $9.9M | $15.3M | $14.7M | $14.4M | $17.0M | ||
Research Expense | -- | -- | $14.7M | $14.4M | $17.0M | ||
Selling, General & Administrative | $12.4M | $18.0M | $17.9M | $18.5M | $23.1M | ||
Selling & Marketing Expenses | $4.9M | $7.7M | $8.5M | $9.5M | -- | ||
General & Administrative Expenses | $7.6M | $10.3M | $9.5M | $18.5M | $23.1M | ||
Depreciation & Amortization | -- | -- | $-290.0K | -- | -- | ||
Depreciation & Amortization | -- | -- | $-290.0K | -- | -- | ||
Amortization | -- | -- | $-290.0K | -- | -- | ||
Other Operating Expenses | -- | -- | $-3.1M | $575.0K | -- | ||
OPERATING INCOME | |||||||
Operating income | $-18.9M | $-30.3M | $-26.5M | $-28.7M | $-33.1M | ||
EBITDA | $-19.5M | $-28.6M | $-26.6M | $-26.4M | $-26.9M | ||
NON-OPERATING ITEMS | |||||||
Interest Expense (Non-Operating) | $543.0K | $67.0K | $174.0K | $770.0K | -- | ||
Intinc | $692.0K | $205.0K | $803.0K | $1.6M | -- | ||
Net Non-Operating Interest Income/Expense | $-149.0K | $310.0K | $629.0K | $-726.0K | -- | ||
Gain on Sale of Securities | $-2.8M | $7.0K | -- | $775.0K | $1.4M | ||
Other Income/Expense | $-2.9M | $7.0K | $-15.0K | $-775.0K | $-1.4M | ||
Other Special Charges | -- | -- | $290.0K | $-146.0K | -- | ||
SPECIAL ITEMS | |||||||
Restructring And Mn A Income | $90.0K | -- | -- | -- | -- | ||
Special Income Charges | $90.0K | -- | $-2.5M | -- | -- | ||
Impairment of Capital Assets | -- | -- | $2.5M | -- | -- | ||
PRE-TAX INCOME | |||||||
EBIT | $-21.0M | $-30.5M | $-28.2M | $-27.3M | $-27.8M | ||
Pre-Tax Income | $-21.6M | $-30.6M | $-28.4M | $-27.3M | $-27.8M | ||
INCOME TAX | |||||||
Tax Provision | $45.0K | $105.0K | $287.0K | $-128.0K | $-2.0K | ||
NET INCOME | |||||||
Net Income | $-21.6M | $-30.7M | $-28.7M | $-27.2M | $-27.8M | ||
Net Income (Continuing Operations) | $-21.6M | $-30.7M | $-28.7M | $-27.2M | $-27.8M | ||
Net Income (Discontinued Operations) | $-21.6M | $-30.7M | $-28.7M | $-27.2M | $-27.8M | ||
Net Income (Common Stockholders) | $-21.6M | $-30.7M | $-28.7M | $-27.2M | $-27.8M | ||
Normalized Income | $-15.8M | $-22.5M | $-18.3M | $-27.4M | $-27.8M | ||
TOTALS | |||||||
Total Expenses | $-26.2M | $-37.2M | $33.2M | -- | $43.7M | ||
SHARE & EPS DATA | |||||||
Average Shares Outstanding | $17.3M | $20.5M | $20.8M | $21.2M | $24.8M | ||
Average Shares Outstanding (Diluted) | $17.3M | $20.5M | $20.8M | $21.2M | $24.8M | ||
Shares Outstanding | $19.6M | $20.8M | $20.3M | $30.1M | $30.1M | ||
Basic EPS | $-1.25 | $-1.5 | $1.38 | $-1.34 | $-1.12 | ||
Basic EPS (Continuing Operations) | $-1.25 | $-1.5 | $1.38 | $-1.34 | $-1.12 | ||
Diluted EPS | $-1.25 | $-1.5 | $1.38 | $-1.34 | $-1.12 | ||
Diluted EPS (Continuing Operations) | $-1.25 | $-1.5 | $1.38 | $-1.34 | $-1.12 | ||
OTHER METRICS | |||||||
Other Costof Revenue | -- | -- | $3.7M | $2.9M | $3.6M | ||
Other Gand A | $7.6M | $10.3M | $9.5M | $18.5M | $23.1M | ||
Restruct | $90.0K | -- | -- | -- | -- |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | PROF | $4.47 | -1.3% | 37.27K |
3 | ||||
4 | ||||
5 | ||||
6 |